Latest Conference Articles

February 17th 2022, 11:40pm

Genitourinary Cancers Symposium (ASCO GU)

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

February 17th 2022, 10:49pm

Genitourinary Cancers Symposium (ASCO GU)

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

February 10th 2022, 5:00pm

PER® Winter Lung Cancer Conference

With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.

February 9th 2022, 12:16am

PER® Winter Lung Cancer Conference

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

February 8th 2022, 10:52pm

PER® Winter Lung Cancer Conference

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

February 8th 2022, 9:38pm

PER® Winter Lung Cancer Conference

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

February 8th 2022, 7:05pm

PER® Winter Lung Cancer Conference

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

February 7th 2022, 10:50pm

PER® Winter Lung Cancer Conference

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.

February 7th 2022, 10:40pm

PER® Winter Lung Cancer Conference

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

February 7th 2022, 10:34pm

PER® Winter Lung Cancer Conference

Antibody-drug conjugates appear to have the most activity in those with non–small cell lung cancer and HER2 expression.

February 7th 2022, 9:55pm

PER® Winter Lung Cancer Conference

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

February 7th 2022, 9:52pm

PER® Winter Lung Cancer Conference

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

February 7th 2022, 9:35pm

PER® Winter Lung Cancer Conference

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

February 5th 2022, 11:17pm

PER® Winter Lung Cancer Conference

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

February 5th 2022, 6:22pm

PER® Winter Lung Cancer Conference

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

February 5th 2022, 6:22pm

PER® Winter Lung Cancer Conference

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

February 5th 2022, 5:59pm

PER® Winter Lung Cancer Conference

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

February 1st 2022, 10:47pm

SGO Winter Meeting

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.

February 1st 2022, 2:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Reviewing some of the most talked about abstracts that were presented at the 2022 Gastrointestinal Cancers Symposium.

January 31st 2022, 10:42pm

SGO Winter Meeting

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.